PPLPHARMA vs WANBURY: Stock Comparison
PIRAMAL PHARMA is the larger company by market capitalisation. PIRAMAL PHARMA shows faster revenue growth and lower leverage, while WANBURY shows a higher ROE, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
PPLPHARMA leads 3; WANBURY leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Live Price | ₹235.9 | ₹187 |
| Day Change | 2.22% | 2.79% |
| Volume | 1.6 Cr | 1.25 L |
| 52-Week High | ₹239.54 | ₹358.85 |
| 52-Week Low | ₹132.3 | ₹161.5 |
| Distance from 52W High | -1.52% | -47.89% |
Valuation
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Market Cap | ₹31,340 Cr | ₹632 Cr |
| P/E Ratio | 0x | 0x |
| P/B Ratio | 3.76x | 0x |
| EPS | ₹-0.52 | ₹4.1 |
| Book Value | ₹61.31 | ₹43.94 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Revenue Growth (TTM YoY) | -0.1% | -19.2% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| ROE | 8.6% | 45.78% |
| ROCE | 9.1% | 25.06% |
| Net Margin | -3.68% | 10.17% |
| Operating Margin | 20.01% | 13.81% |
| Debt to Equity | 0.09x | 1.49x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | PPLPHARMA | WANBURY |
|---|---|---|
| Promoter Holding | 34.8% | 34.33%▼ 0.03 pp |
| FII Holding | 13.65%▲ 1.13 pp | 0.71%▼ 0.18 pp |
| DII Holding | 14.44%▼ 0.13 pp | 0.02%▼ 0.04 pp |
| Public Holding | 36.71%▼ 0.92 pp | 56.28%▲ 0.25 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: PIRAMAL PHARMA and WANBURY.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.